Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| APGE | 8-K | bullish | 7/10 | Apogee Therapeutics stockholders voted overwhelmingly to approve the $135.11/share all-cash acquisition by AbbVie, with | Aug 11, 2026 |
| KYTX | PRESS-RELEASE | neutral | 5/10 | Kyverna Therapeutics reported Q2 2026 net loss of $0.63 per share, beating consensus of -$0.68 by 7.4%. The company high | Aug 11, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced positive in vitro permeation results for its intranasal MEAI formulation, showing 97.35% cu | Aug 11, 2026 |
| MAZE | PRESS-RELEASE | neutral | 4/10 | Maze Therapeutics reported Q2 2026 EPS of -$0.76, missing consensus of -$0.70 by 8.6%, with no license revenue for the q | Aug 11, 2026 |
| AQST | PRESS-RELEASE | neutral | 5/10 | Aquestive reported Q2 2026 revenue of $13.8M, beating the $11.6M consensus, but GAAP EPS of -$0.18 missed the -$0.12 con | Aug 11, 2026 |
| IKT | PRESS-RELEASE | neutral | 5/10 | Inhibikase Therapeutics reported Q2 2026 net loss of $0.11 per share, in line with the year-ago period but with a net lo | Aug 11, 2026 |
| ERAS | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 11, 2026 |
| ANTX | 8-K | neutral | 4/10 | AN2 Therapeutics reported Q2 2026 net loss of $8.2M ($0.18/share) vs $6.5M ($0.21/share) in Q2 2025, with net loss per s | Aug 11, 2026 |
| TSHA | PRESS-RELEASE | neutral | 5/10 | Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs. $1.99M | Aug 11, 2026 |
| TXMD | 8-K | bearish | 5/10 | TherapeuticsMD reported Q2 2026 results showing declining license revenue ($869K vs $952K YoY) and net income ($164K vs | Aug 11, 2026 |
| GMAB | 6-K | neutral | 2/10 | Genmab filed a 6-K reporting a routine capital increase of 24,592 shares from employee warrant exercises, raising approx | Aug 11, 2026 |
| FTH | 144 | bearish | 5/10 | Cambrian BioPharma Inc, a 10% stockholder of Faeth Therapeutics, filed a Form 144 notice of intent to sell 130,142 share | Aug 11, 2026 |
| AMPH | 144 | neutral | 2/10 | Director Richard Prins filed a Form 144 notice of intent to sell 7,973 shares of Amphastar Pharmaceuticals common stock, | Aug 11, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K reporting a routine transaction by Maya Martinez-Davis, President US, who acquired 9.016 notional A | Aug 11, 2026 |
| ACIU | 6-K | bullish | 6/10 | AC Immune received FDA Fast Track designation and IND clearance for its wholly owned anti-alpha-synuclein active immunot | Aug 11, 2026 |
| BIXT | 8-K | bullish | 5/10 | Bioxytran reported encouraging clinical observations from the first CIDP patient treated with PLICID, a galectin antagon | Aug 11, 2026 |
| BTAI | 8-K | bearish | 7/10 | BioXcel Therapeutics entered its Twelfth Amendment to the Oaktree credit agreement, extending the deadline to August 21, | Aug 11, 2026 |
| HBIO | 8-K | mixed | 5/10 | Harvard Bioscience filed an 8-K with an investor presentation providing updated FY26 guidance: revenue growth raised to | Aug 11, 2026 |
| UPB | 8-K | neutral | 4/10 | Upstream Bio reported Q2 2026 financial results with a net loss of $39.7M, roughly in line with the $40.0M loss in Q2 20 | Aug 11, 2026 |
| IMUX | 8-K | neutral | 5/10 | Immunic reported Q2 2026 net loss of $34.1M ($0.80/share), roughly matching the Street consensus of -$1.24 (narrower los | Aug 11, 2026 |
| COAG | 8-K | bullish | 7/10 | Hemab Therapeutics reported Q2 2026 net loss of $24.2M ($0.80/share), wider than the $12.2M loss in Q2 2025 but in line | Aug 11, 2026 |
| CCCC | 8-K | neutral | 5/10 | C4 Therapeutics reported Q2 2026 revenue of $6.6M (up 2.7% YoY) and a net loss of $23.6M ($0.18 per share), beating the | Aug 11, 2026 |
| VREOF | 8-K | mixed | 6/10 | Vireo Growth reported Q2 2026 GAAP revenue of $209.3M (+335% YoY), massively beating the $167.4M consensus, but GAAP EPS | Aug 11, 2026 |
| CALC | 8-K | bearish | 6/10 | CalciMedica reported Q2 2026 financial results with a net loss of $7.7M ($0.45/share), wider than the $6.0M loss in Q2 2 | Aug 11, 2026 |
| ACHV | PRESS-RELEASE | bearish | 7/10 | Achieve Life Sciences reported Q2 2026 EPS of -$0.80, significantly missing the consensus estimate of -$0.16, driven by | Aug 11, 2026 |
| FENC | PRESS-RELEASE | bullish | 6/10 | Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1M, up 78% YoY from $9.7M, and GAAP diluted EPS of $0.0 | Aug 11, 2026 |
| TNGX | 8-K | bullish | 7/10 | Tango Therapeutics reported Q2 2026 financial results, highlighting a net loss of $55.3M ($0.37/share) vs $38.9M ($0.35/ | Aug 11, 2026 |
| MREO | 8-K | mixed | 6/10 | Mereo BioPharma reported Q2 2026 results with a net loss of $7.0M, improved from a $14.6M loss in Q2 2025, driven by red | Aug 11, 2026 |
| RARE | 8-K | neutral | 4/10 | Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, | Aug 11, 2026 |
| PDSB | 8-K | bearish | 7/10 | PDS Biotechnology announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (mCRC) and disconti | Aug 11, 2026 |